Literature DB >> 7927412

Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

U Andersson1, L Björk, U Skansén-Saphir, J Andersson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7927412     DOI： 10.1111/j.1600-065x.1994.tb00855.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  31 in total

1.  Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  Intravenous immunoglobulin preparation attenuates LPS-induced production of pro-inflammatory cytokines in human monocytic cells by modulating TLR4-mediated signaling pathways.

Authors:  Kazuki Murakami; Chiaki Suzuki; Fujio Kobayashi; Atsushi Nakano; Akihiro Fujii; Kaoru Sakai; Teruaki Imada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-31       Impact factor: 3.000

Review 5.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 6.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 7.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

8.  Variability of the inhibition by total immunoglobulin of in vitro autoantibody-mediated erythrophagocytosis by mouse macrophages.

Authors:  S Léonard; I Pierard; T E Michaelsen; S Izui; P L Masson; J-P Coutelier
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

9.  Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.

Authors:  Sevim Barbasso Helmers; Maryam Dastmalchi; Helene Alexanderson; Inger Nennesmo; Mona Esbjörnsson; Björn Lindvall; Ingrid E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

10.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.